Page last updated: 2024-09-05

sorafenib and Cancer of Cervix

sorafenib has been researched along with Cancer of Cervix in 6 studies

Research

Studies (6)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	4 (66.67)	24.3611
2020's	2 (33.33)	2.80

Authors

Authors	Studies
He, SL; Li, LJ; Wang, C; Xue, M; Zeng, J	1
El-Khouly, OA; El-Messery, SM; El-Sayed, MA; Henen, MA	1
Al Ghazal, A; Arndt, A; Cronauer, MV; Kraft, K; Müller, J; Schrader, AJ; Schrader, M; Skowronek, P; Steinestel, J; Steinestel, K	1
Berger, W; Dornetshuber-Fleiss, R; Heffeter, P; Heilos, D; Lemmens-Gruber, R; Mohr, T; Novicky, A; Richter, L; Süssmuth, RD; Zlesak, M	1
Chaudary, N; Clarke, B; Fan, S; Fyles, A; Glicksman, R; Haider, M; Hill, RP; Kim, S; MacKay, H; Milosevic, MF; Oza, AM; Pintilie, M; Townsley, CA; Yeung, I	1
Cheng, CW; Hsieh, YH; Lin, CL; Lin, MT; Lin, TY; Tsai, JP; Wu, CC; Yang, SF	1

Trials

1 trial(s) available for sorafenib and Cancer of Cervix

Article	Year
Sorafenib Increases Tumor Hypoxia in Cervical Cancer Patients Treated With Radiation Therapy: Results of a Phase 1 Clinical Study. International journal of radiation oncology, biology, physics, 2016, Jan-01, Volume: 94, Issue:1 Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Biomarkers; Brachytherapy; Carcinoma, Squamous Cell; Cell Hypoxia; Chemoradiotherapy; Cisplatin; Drug Administration Schedule; Early Termination of Clinical Trials; Female; Follow-Up Studies; Humans; Niacinamide; Oxygen; Partial Pressure; Phenylurea Compounds; Radiation Tolerance; Sorafenib; Time Factors; Tumor Burden; Uterine Cervical Neoplasms	2016

Article

Year

Sorafenib Increases Tumor Hypoxia in Cervical Cancer Patients Treated With Radiation Therapy: Results of a Phase 1 Clinical Study.

International journal of radiation oncology, biology, physics, 2016, Jan-01, Volume: 94, Issue:1

Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Biomarkers; Brachytherapy; Carcinoma, Squamous Cell; Cell Hypoxia; Chemoradiotherapy; Cisplatin; Drug Administration Schedule; Early Termination of Clinical Trials; Female; Follow-Up Studies; Humans; Niacinamide; Oxygen; Partial Pressure; Phenylurea Compounds; Radiation Tolerance; Sorafenib; Time Factors; Tumor Burden; Uterine Cervical Neoplasms

2016

Other Studies

5 other study(ies) available for sorafenib and Cancer of Cervix

Article	Year
Cdc25A inhibits autophagy-mediated ferroptosis by upregulating ErbB2 through PKM2 dephosphorylation in cervical cancer cells. Cell death & disease, 2021, 11-06, Volume: 12, Issue:11 Topics: Animals; Autophagy; Carrier Proteins; cdc25 Phosphatases; Cell Line, Tumor; Female; Ferroptosis; Gene Expression Regulation, Neoplastic; Humans; Male; Membrane Proteins; Mice, Nude; Phosphorylation; Receptor, ErbB-2; RNA, Messenger; Signal Transduction; Sorafenib; Thyroid Hormone-Binding Proteins; Thyroid Hormones; Up-Regulation; Uterine Cervical Neoplasms	2021
Design, synthesis and computational study of new benzofuran hybrids as dual PI3K/VEGFR2 inhibitors targeting cancer. Scientific reports, 2022, 10-12, Volume: 12, Issue:1 Topics: Antineoplastic Agents; Benzofurans; Breast Neoplasms; Cell Proliferation; Drug Design; Drug Screening Assays, Antitumor; Female; Humans; MCF-7 Cells; Molecular Docking Simulation; Molecular Structure; Phosphatidylinositol 3-Kinases; Protein Kinase Inhibitors; Sorafenib; Structure-Activity Relationship; Uterine Cervical Neoplasms; Vascular Endothelial Growth Factor Receptor-2	2022
Overexpression of p16(INK4a) in urothelial carcinoma in situ is a marker for MAPK-mediated epithelial-mesenchymal transition but is not related to human papillomavirus infection. PloS one, 2013, Volume: 8, Issue:5 Topics: Aged; Carcinoma in Situ; Cell Line, Tumor; Cyclin-Dependent Kinase Inhibitor p16; Epithelial-Mesenchymal Transition; Female; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; Male; MAP Kinase Signaling System; Mitogen-Activated Protein Kinases; Niacinamide; Papillomaviridae; Papillomavirus Infections; Phenylurea Compounds; Sorafenib; Transfection; Urokinase-Type Plasminogen Activator; Urothelium; Uterine Cervical Dysplasia; Uterine Cervical Neoplasms	2013
The naturally born fusariotoxin enniatin B and sorafenib exert synergistic activity against cervical cancer in vitro and in vivo. Biochemical pharmacology, 2015, Feb-01, Volume: 93, Issue:3 Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Depsipeptides; Dose-Response Relationship, Drug; Drug Synergism; Female; Human Umbilical Vein Endothelial Cells; Humans; Male; Mice; Mice, SCID; Niacinamide; Phenylurea Compounds; Sorafenib; T-2 Toxin; Uterine Cervical Neoplasms; Xenograft Model Antitumor Assays	2015
Synergistic effect of fisetin combined with sorafenib in human cervical cancer HeLa cells through activation of death receptor-5 mediated caspase-8/caspase-3 and the mitochondria-dependent apoptotic pathway. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 2016, Volume: 37, Issue:5 Topics: Animals; Apoptosis; Caspase 3; Caspase 8; Cell Line, Tumor; Cell Proliferation; Cell Survival; Disease Models, Animal; Drug Synergism; Female; Flavonoids; Flavonols; HeLa Cells; Humans; Membrane Potential, Mitochondrial; Mitochondria; Niacinamide; Phenylurea Compounds; Receptors, TNF-Related Apoptosis-Inducing Ligand; Signal Transduction; Sorafenib; Tumor Burden; Uterine Cervical Neoplasms; Xenograft Model Antitumor Assays	2016